ANGLE plc (AIM:AGL)
Market Cap | 6.75M |
Revenue (ttm) | 2.62M |
Net Income (ttm) | -15.78M |
Shares Out | 321.53M |
EPS (ttm) | -0.05 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,907,053 |
Average Volume | 2,533,778 |
Open | 2.075 |
Previous Close | 2.200 |
Day's Range | 1.900 - 2.374 |
52-Week Range | 1.500 - 17.450 |
Beta | 0.08 |
RSI | 27.72 |
Earnings Date | Dec 10, 2025 |
About ANGLE
ANGLE plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of... [Read more]
Financial Performance
In 2024, ANGLE's revenue was 2.86 million, an increase of 30.92% compared to the previous year's 2.19 million. Losses were -14.23 million, -29.34% less than in 2023.
Financial StatementsNews

AIM Market Roundup: WH Ireland, Bradda Head, Oxford Biodynamics
WH Ireland, Bradda Head, Oxford Biodynamics are today's top risers, while Mercantile Ports, Angle take the biggest fall on London's AIM market

Angle PLC Announces Strategy Update
Appointment of Executive Chairman, proposed change of name and strategy update Company to pursue revised strategy and name change to CelLBxHealth plc Dr. Jan Groen, the current Non-Executive Chairman ...

Angle PLC Announces Presentation of Data on Glioblastoma
CLINICAL study SHOWS DETECTION OF CTCs in glioblastoma Patients GBM CTC isolation only possible with Parsortix label-free methodology Data presented at the 7th ACTC meeting GUILDFORD, SURREY / ACCESS ...

Angle PLC Announces Board Changes
GUILDFORD, SURREY / ACCESS Newswire / September 12, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in re...
ANGLE plc ADR 2025 Q2 - Results - Earnings Call Presentation
ANGLE PLC (ANPCY) (Half Year 2025) Earnings Call Highlights: Strategic Collaborations and ...
ANGLE PLC (ANPCY) (Half Year 2025) Earnings Call Highlights: Strategic Collaborations and Market Challenges
Half Year 2025 Angle PLC Earnings Call Transcript
Half Year 2025 Angle PLC Earnings Call Transcript
ANGLE Plc ADR (ANPCY) Q2 2025 Earnings Call Transcript

Angle PLC Announces Interim Results
ANGLE plc ("ANGLE" or "the Company") Interim Results for the six months ended 30 June 2025 COMMERCIALISATION PROGRESSED ACROSS MULTIPLE FRONTS DESPITE REVENUE PRESSURE FROM ADVERSE MARKET CONDITIONS L...

Angle PLC Announces Change of Adviser
APPOINTMENT OF NOMINATED ADVISER AND SOLE BROKER GUILDFORD, SURREY / ACCESS Newswire / September 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circu...

Angle PLC Announces Notice of Results
ANGLE plc ("the Company") Notice of Interim Results and Webcast GUILDFORD, SURREY / ACCESS Newswire / September 5, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with i...
ANGLE plc partners with Myriad Genetics to advance cancer diagnostics

ANGLE Announces Collaboration with Myriad Genetics
Assessment of feasibility for use of Parsortix derived circulating tumour cell (CTC) DNA with Myriad Genetics' existing tissue-based diagnostic test GUILDFORD, SURREY / ACCESS Newswire / August 20, 20...

Was Rapper Fazilpuria Shot At By Friends? Rs 5 Crore Angle Emerges
New details have emerged in the firing incident involving Haryanvi singer-rapper Rahul Yadav alias Fazilpuria, who narrowly escaped death Tuesday night after being shot at twice in Gurugram.

Angle, Task: How To Write Better Artificial Intelligence Prompts
As tools such as ChatGPT, Copilot and other generative artificial intelligence (AI) systems become part of everyday workflows, more companies are looking for employees who can answer "yes" to this que...

Angle PLC Announces Parsortix Enables Study Of Cancer Progression
New publication in Nature Genetics using Parsortix identifies CTC clusters as promising targets to stop the spread of cancer GUILDFORD, SURREY / ACCESS Newswire / July 8, 2025 / ANGLE plc (AIM:AGL)(OT...

ANGLE PLC Announces Result of 2025 Annual General Meeting
Result of 2025 Annual General Meeting GUILDFORD, SURREY / ACCESS Newswire / June 30, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual Genera...

Angle PLC - EACR 2025: Data Demonstrating DNA Dual Analysis
ANGLE presents new data at EACR 2025 DEMONSTRATING DNA DUAL ANALYSIS FOR COMPREHENSIVE LIQUID BIOPSY PROFILING Poster highlights ANGLE's combined CTC-DNA and ctDNA analysis revealing tumour heterogene...

Angle PLC - EACR 2025: Innovation in AR Expression Profiling
ANGLE presents new data at EACR 2025 Highlighting Innovation in Androgen Receptor EXPRESSION profiling Poster presentation highlights development of a novel CTC-based assay GUILDFORD, SURREY / ACCESS ...

ANGLE plc Announces Novel Discoveries Into the Biology of Cancer
PARSORTIX SYSTEM enableS novel DISCOVERIES into the biology of cancer Academic and translational research is the driving force behind the pipeline of next generation cancer therapeutics GUILDFORD, SUR...

Angle PLC Announces Posting of Annual Report and Notice of AGM
GUILDFORD, SURREY / ACCESS Newswire / June 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research...

Angle PLC Announces Board Changes
GUILDFORD, UNITED KINGDOM / ACCESS Newswire / June 6, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in ...

Angle PLC Announces Preliminary Results
Commercialization building with large pharma contracts secured Further progress on next generation sequencing assays for DNA dual analysis of CTC-DNA and ctDNA GUILDFORD, UNITED KINGDOM / ACCESS Newsw...

Angle PLC Announces Notice of Results
Notice of Preliminary Results and Webcast GUILDFORD, SURREY / ACCESS Newswire / May 23, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumou...

Angle PLC Announces Results of Eisai Phase 2 pilot study
UPDATE ON ASTRAZENECA ASSAY DEVELOPMENT PROJECTS AND SUCCESSFUL COMPLETION OF EISAI CONTRACT Development of both the prostate cancer androgen receptor assay and the multi-cancer DDR micronuclei assay ...